This dataset contains counts of live births for California counties based on information entered on birth certificates. Final counts are derived from static data and include out of state births to California residents, whereas provisional counts are derived from incomplete and dynamic data. Provisional counts are based on the records available when the data was retrieved and may not represent all births that occurred during the time period.

The final data tables include both births that occurred in California regardless of the place of residence (by occurrence) and births to California residents (by residence), whereas the provisional data table only includes births that occurred in California regardless of the place of residence (by occurrence). The data are reported as totals, as well as stratified by parent giving birth's age, parent giving birth's race-ethnicity, and birth place type. See temporal coverage for more information on which strata are available for which years.

This statistical release presents the most recent monthly figures for NHS-funded maternity services in England, from data submitted to the Maternity Services Data Set (MSDS). This is the latest report from the newest version of the data set, MSDS.v.2, which has been in place since April 2019. The new data set was a significant change which added support for key policy initiatives such as continuity of carer, as well as increased flexibility through the introduction of new clinical coding. This was a major change, so data quality and coverage initially reduced from the levels seen in earlier publications. MSDS.v.2 data completeness improved over time, and we are looking at ways of supporting further improvements. This month four new measures have been included in this publication for the first time: reporting where safeguarding concerns have been raised during the pregnancy for the mother or the unborn child. This new data can be found in the Measures file available for download and further information on the new measures can be found in the accompanying Metadata file. Data derived from SNOMED codes is used in some measures such as those for smoking at booking and delivery, and birth weight, and others will follow in later publications. SNOMED data is also included in some of the published Clinical Quality Improvement Metrics (CQIMs), where rules have been applied to ensure measure rates are calculated only where data quality is high enough. System suppliers are at different stages of development and delivery to trusts. In some cases, this has limited the aspects of data that can be submitted in the MSDS. To help Trusts understand to what extent they met the Clinical Negligence Scheme for Trusts (CNST) Maternity Incentive Scheme (MIS) Data Quality Criteria for Safety Action 2, we have been producing a CNST Scorecard Dashboard showing trust performance against this criteria. This dashboard, now rebranded as the Maternity and Neonatal Programme MSDS Data Quality Priorities dashboard, can be accessed via the link below, includes data for July 2023 which is the assessment month for several of the criteria - and also the most recent data, for August and September 2023. These statistics are classified as experimental and should be used with caution. Experimental statistics are new official statistics undergoing evaluation. More information about experimental statistics can be found on the UK Statistics Authority website. The percentages presented in this report are based on rounded figures and therefore may not total to 100%.

This is a publication on maternity activity in English NHS hospitals. This report examines data relating to delivery and birth episodes in 2023-24, and the booking appointments for these deliveries. This annual publication covers the financial year ending March 2024. Data is included from both the Hospital Episodes Statistics (HES) data warehouse and the Maternity Services Data Set (MSDS). HES contains records of all admissions, appointments and attendances for patients admitted to NHS hospitals in England. The HES data used in this publication are called 'delivery episodes'. The MSDS collects records of each stage of the maternity service care pathway in NHS-funded maternity services, and includes information not recorded in HES. The MSDS is a maturing, national-level dataset. In April 2019, the MSDS transitioned to a new version of the dataset. This version, MSDS v2.0, is an update that introduced a new structure and content - including clinical terminology, in order to meet current clinical practice and incorporate new requirements. It is designed to meet requirements that resulted from the National Maternity Review, which led to the publication of the Better Births report in February 2016. This is the fifth publication of data from MSDS v2.0 and data from 2019-20 onwards is not directly comparable to data from previous years. This publication shows the number of HES delivery episodes during the period, with a number of breakdowns including by method of onset of labour, delivery method and place of delivery. It also shows the number of MSDS deliveries recorded during the period, with a breakdown for the mother's smoking status at the booking appointment by age group. It also provides counts of live born term babies with breakdowns for the general condition of newborns (via Apgar scores), skin-to-skin contact and baby's first feed type - all immediately after birth. There is also data available in a separate file on breastfeeding at 6 to 8 weeks. For the first time information on 'Smoking at Time of Delivery' has been presented using annual data from the MSDS. This includes national data broken down by maternal age, ethnicity and deprivation. From 2025/2026, MSDS will become the official source of 'Smoking at Time of Delivery' information and will replace the historic 'Smoking at Time of Delivery' data which is to become retired. We are currently undergoing dual collection and reporting on a quarterly basis for 2024/25 to help users compare information from the two sources. We are working with data submitters to help reconcile any discrepancies at a local level before any close down activities begin. A link to the dual reporting in the SATOD publication series can be found in the links below. Information on how all measures are constructed can be found in the HES Metadata and MSDS Metadata files provided below. In this publication we have also included an interactive Power BI dashboard to enable users to explore key NHS Maternity Statistics measures. The purpose of this publication is to inform and support strategic and policy-led processes for the benefit of patient care. This report will also be of interest to researchers, journalists and members of the public interested in NHS hospital activity in England. Any feedback on this publication or dashboard can be provided to enquiries@nhsdigital.nhs.uk, under the subject “NHS Maternity Statistics”.

The number of maternal deaths and maternal mortality rates for selected causes, 2000 to most recent year.

This is a publication on maternity activity in English NHS hospitals. This report examines data relating to delivery and birth episodes in 2022-23, and the booking appointments for these deliveries. This annual publication covers the financial year ending March 2023. Data is included from both the Hospital Episodes Statistics (HES) data warehouse and the Maternity Services Data Set (MSDS). HES contains records of all admissions, appointments and attendances for patients admitted to NHS hospitals in England. The HES data used in this publication are called 'delivery episodes'. The MSDS collects records of each stage of the maternity service care pathway in NHS-funded maternity services, and includes information not recorded in HES. The MSDS is a maturing, national-level dataset. In April 2019 the MSDS transitioned to a new version of the dataset. This version, MSDS v2.0, is an update that introduced a new structure and content - including clinical terminology, in order to meet current clinical practice and incorporate new requirements. It is designed to meet requirements that resulted from the National Maternity Review, which led to the publication of the Better Births report in February 2016. This is the fourth publication of data from MSDS v2.0 and data from 2019-20 onwards is not directly comparable to data from previous years. This publication shows the number of HES delivery episodes during the period, with a number of breakdowns including by method of onset of labour, delivery method and place of delivery. It also shows the number of MSDS deliveries recorded during the period, with breakdowns including the baby's first feed type, birthweight, place of birth, and breastfeeding activity; and the mothers' ethnicity and age at booking. There is also data available in a separate file on breastfeeding at 6 to 8 weeks. The count of Total Babies includes both live and still births, and previous changes to how Total Babies and Total Deliveries were calculated means that comparisons between 2019-20 MSDS data and later years should be made with care. Information on how all measures are constructed can be found in the HES Metadata and MSDS Metadata files provided below. In this publication we have also included an interactive Power BI dashboard to enable users to explore key NHS Maternity Statistics measures. The purpose of this publication is to inform and support strategic and policy-led processes for the benefit of patient care. This report will also be of interest to researchers, journalists and members of the public interested in NHS hospital activity in England. Any feedback on this publication or dashboard can be provided to enquiries@nhsdigital.nhs.uk, under the subject “NHS Maternity Statistics”.

Live births in the UK by area of usual residence of mother. The tables contain summary data for local authorities and local health boards (within Wales) including figures by age of mother.

Number and percentage of live births, by month of birth, 1991 to most recent year.

Mean age of mother at time of delivery, 1991 to most recent year.

(+966505195917)☎️

Where to buy Abortion (cytotec)pills in kuwait(+966505195917)☎️

Abortion pills in al Farwaniyah, Kuwait |abortion pills in Al Asimah, Kuwait |(+966505195917)abortion pills in Al Ahmadi, Kuwait |abortion pills in Al Jahra, Kuwait |(+966505195917)

Abortion pills in Hawalli, Kuwait |(+966505195917)☎️

Abortion(cytotec) pills in Kuwait City, Kuwait |(+966505195917)☎️

Abortion pills in Mubarak Al-Kabeer, Kuwait(+966505195917) | ☎️abortion (cytotec)pills in Salmiya Kuwait (+966505195917)☎️

Abortion (cytotec)pills in Oman:-Muscat,Adam.

As Sib.(+966505195917)☎️

Al Ashkharah.

Al Buraimi.

Al Hamra.(+966505195917)☎️

Al Jazer.

Al Madina A'Zarqa (formerly known as Blue City)(+966505195917)☎️

Al Suwaiq.Qatar,Dubai UAE(+966505195917)☎️

Abortion(cytotec) pills in Saudi Arabia ★+966505195917★☎️

Abortion pills in Riyadh

Abortion pills in Jeddah

Abortion pills in dammam

Abortion pills in taif

Abortion pills in tabuk

Abortion pills in Makkah,madina

Abortion (cytotec)pills in Qatar doha ★+966505195917☎️

What is Abortion ?

★+966505195917☎️

An abortion is medically referred to as a therapeutic abortion when it is performed to save the life of the pregnant woman; to prevent harm to the woman's physical or mental health; to terminate a pregnancy where indications are that the child will have a significantly increased chance of mortality or morbidity; or to …An induced abortion is different from a spontaneous abortion. That is the loss of a pregnancy before the 20th week of pregnancy. It is more commonly known as a miscarriage.

★+966505195917☎️

★+966505195917☎️

Kind of abortion :

★+966505195917☎️

There are 2 types of abortion:

1.Medical, which uses (cytotec)medication.

2.Surgical, which involves a small operation.

+966505195917☎️

+966505195917☎️

Medical abortion (cytotec)procedure:

+966505195917☎️

Mifepristone 200mg

Misoprostal 200mg

(Cytotec ) Pfizer is an American brand used to terminate pregnancy.

+966505195917☎️

How mifepristone work?

+966505195917☎️

Mifepristone is a medication used in medical abortion (abortion pill) procedures. It works by blocking the hormone progesterone, which is necessary to maintain the lining of the uterus where a fertilized egg would normally implant and develop. Without progesterone, the lining breaks down, making it difficult for the pregnancy to continue. Mifepristone is often used in combination with another medication called misoprostol to induce contractions and complete the abortion process.

☎️+966505195917☎️

How misoprostal (cytotec)work?

☎️+966505195917☎️

Misoprostol is a medication that is used in combination with mifepristone for medical abortions. It works primarily by causing contractions of the uterus, which helps expel the contents of the uterus, including the embryo or fetus.

☎️+966505195917☎️

Here's how misoprostol (cytotec)works in the context of abortion:

+966505195917☎️

Softening of the cervix: Misoprostol helps soften the cervix (the lower part of the uterus), which makes it easier for the uterus to expel its contents.

+966505195917☎️

Uterine contractions: It stimulates strong uterine contractions, similar to those that occur during labor, to expel the pregnancy tissue.

☎️+966505195917★᭄

Completing the abortion process: When used after mifepristone, misoprostol ensures the expulsion of the remaining contents of the uterus, completing the abortion process.

☎️+966505195917★

Medical abortions using mifepristone and misoprostol are generally safe and effective when used according to medical guidelines and under medical supervision.

★+966505195917★☎️

Medical abortion(cytotec) guidline :

★☎️+966505195917★

For medical abortion at < 12 weeks:

1.Recommend the use of 200 mg mifepristone administered orally, followed 1–2 days later by 800 μg misoprostol administered vaginally, sublingually or buccally. ...

2.When using misoprostol alone: Recommend the use of 800 μg misoprostol administered buccally, sublingually or vaginally.

Surgical Abortion guidline:

★☎️+966505195917

Surgical abortion, also known as suction aspiration abortion, can be performed in a one-day procedure if less than 14 weeks have passed since the first day of your last menstrual period. The procedure is done in the doctor's office with local anesthesia and oral pain-relieving medications.

★+966505195917★☎️

The reasons for having an (cytotec)abortion are:

★+966505195917★

Don't want to have children because you are worried it will disrupt your career.

Don't want to have children without a father.

Pregnant due to infidelity.

Pregnant out of wedlock.

The child's condition is still small.

Pregnancy conditions that are dangerous for the mother.

Abortion performed against a defective fetus.

Abortion done for other reasons.

★+966505195917★☎️

Side Effects of the Abortion (cytotec)Drug Cytotec Misoprostol

★+966505195917★☎️

Nausea or stomach cramps may occur. If any of these effects persist or worsen, notify us immediately.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this drug do not have serious side effects.

Diarrhea is common with the drug misoprostol and usually occurs about two weeks after you start taking it, and lasts for about a week. Make sure to maintain fluid and mineral/electrolyte intake to prevent dehydration. Persistent diarrhea can sometimes cause major losses of body fluids and minerals. Tell your doctor immediately if you experience any of these serious signs of dehydration and mineral imbalance, severe dizziness.

★☎️+966505195917★

ADVANTAGES OF CYTOTEC (medical) TERMINATION DRUG:

★+966505195917★☎️

Abort the pregnancy quickly and completely.

The results after taking cytotec and gastrul drugs are like a natural miscarriage.

It doesn't cost much.

Can be used in early pregnancy.

No need for surgical intervention.

6.Success rate reaches 99%.

★+966505195917★

Abortion is carried out by pregnant women, both married and unmarried, for various reasons, but the main reasons are non-medical reasons (including self-abortion/intentional/artificial)

★+966505195917★

Usage of (cytotec)abortion pills:

(As prescribed by the physician)

★☎️+966505195917★☎️

Appeal: For those of you who really want to abort a pregnancy, now there are lots of patients who come and complain about the circulation of fake abortion drugs being sold. We advise you not to be tempted by cheap abortion drug prices.

★☎️+966505195917★☎️

Note: An error was identified in Table 6 of these National tables. As part of the process to thoroughly quality assure the rest of the publication, two further errors were found. These affect Table 9 in the National tables, Table 6 in the SHA tables and Table 3 in the PCT tables. None of the errors affect any key national figures. These errors have now been rectified. In Table 6 of the National tables the number of successful quitters per 100,000 population for England has been amended. In Table 9 of the National tables and Table 6 of the SHA tables, the data submitted by one PCT for NS-SEC (socio-economic classification) was incomplete. The numbers and corresponding percentages in the 'unable to code' category have been amended. A percentage in Table 3 of the PCT tables was incorrect. Other columns in this table were unaffected. Here a mistake was made when suppressing unsafe cells. Please see tables for details of amendments. Summary: This quarterly report presents provisional results from the monitoring of the NHS Stop Smoking Services (NHS SSS) in England during the period April to December 2008. This report includes information on the number of people setting a quit date and the number who successfully quit at the 4 week follow-up. It also presents more in depth analyses of the key measures of the service including pregnant women; breakdowns by ethnic groups and type of pharmacotherapy received; regional analyses at Strategic Health Authority (SHA) and Primary Care Trust (PCT) levels. This release also sees the inclusion of more detailed PCT results for the first time. In 2008/09 there have been new data items added to the collection. This includes data for the number of people setting a quit date and the number who successfully quit at the 4 week follow-up categorised by socio economic classification, eligibility to receive free prescriptions, intervention setting and intervention type. This bulletin reports on these newly collected data items. However there are weaknesses with this newly collected data as is common with new data collections within their first year, but rather than withhold this already useful dataset we are releasing it labelled 'experimental statistics' and are seeking input from users to help us improve it.